|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM171445821 |
| 003 |
DE-627 |
| 005 |
20231223125706.0 |
| 007 |
tu |
| 008 |
231223s2007 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0572.xml
|
| 035 |
|
|
|a (DE-627)NLM171445821
|
| 035 |
|
|
|a (NLM)17627891
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tokuriki, Shuko
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Leukotriene D(4) enhances the function of endothelin-1-primed fibroblasts
|
| 264 |
|
1 |
|c 2007
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.11.2007
|
| 500 |
|
|
|a Date Revised 03.12.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Airway inflammation is accompanied by structural changes, termed remodeling, that lead to lung dysfunction over the long term. Although both endothelin-1 (ET-1) and cysteinyl leukotrienes (CysLTs) appear to be involved in airway remodeling in several lung diseases, how these molecules interact remains largely unknown. In this study, we examined the effects of leukotriene (LT) D(4) on the function of ET-1-primed fibroblasts. ET-1 at 10(-7) M up-regulated the expression of the CysLT receptors at both the mRNA and protein levels in human lung fibroblasts. LTD(4) enhanced matrix metalloproteinase-2 and pro-collagen production, and alpha-smooth muscle actin expression of ET-1-primed fibroblasts, but had little or no effect on unprimed fibroblasts. The CysLT1 receptor antagonist montelukast completely abrogated the effects of LTD(4). Our data suggested that LTD(4) may act as a precipitating factor during ET-1-mediated airway remodeling and that CysLT1 receptor antagonists may have a role in preventing aberrant extracellular matrix degradation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Acetates
|2 NLM
|
| 650 |
|
7 |
|a Actins
|2 NLM
|
| 650 |
|
7 |
|a Cyclopropanes
|2 NLM
|
| 650 |
|
7 |
|a Endothelin-1
|2 NLM
|
| 650 |
|
7 |
|a Leukotriene Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 650 |
|
7 |
|a Procollagen
|2 NLM
|
| 650 |
|
7 |
|a Quinolines
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Leukotriene
|2 NLM
|
| 650 |
|
7 |
|a Sulfides
|2 NLM
|
| 650 |
|
7 |
|a Tissue Inhibitor of Metalloproteinases
|2 NLM
|
| 650 |
|
7 |
|a Transforming Growth Factor beta1
|2 NLM
|
| 650 |
|
7 |
|a procollagen type I carboxy terminal peptide
|2 NLM
|
| 650 |
|
7 |
|a Leukotriene D4
|2 NLM
|
| 650 |
|
7 |
|a 73836-78-9
|2 NLM
|
| 650 |
|
7 |
|a Matrix Metalloproteinases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.24.-
|2 NLM
|
| 650 |
|
7 |
|a leukotriene D4 receptor
|2 NLM
|
| 650 |
|
7 |
|a LRF7RW46ID
|2 NLM
|
| 650 |
|
7 |
|a montelukast
|2 NLM
|
| 650 |
|
7 |
|a MHM278SD3E
|2 NLM
|
| 700 |
1 |
|
|a Ohshima, Yusei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamada, Akiko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohta, Naoko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsukahara, Hirokazu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mayumi, Mitsufumi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 125(2007), 1 vom: 04. Okt., Seite 88-94
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:125
|g year:2007
|g number:1
|g day:04
|g month:10
|g pages:88-94
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 125
|j 2007
|e 1
|b 04
|c 10
|h 88-94
|